Home  |  Contact

Cellosaurus MDA-MB-231/PacR (CVCL_4Z64)

[Text version]

Cell line name MDA-MB-231/PacR
Accession CVCL_4Z64
Resource Identification Initiative To cite this cell line use: MDA-MB-231/PacR (RRID:CVCL_4Z64)
Comments Group: Triple negative breast cancer (TNBC) cell line.
Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol).
Sequence variations Heterozygous for BRAF p.Gly464Val (c.1391G>T) (ClinVar=VCV000040364) (from parent cell line).
Homozygous for CDKN2A deletion (from parent cell line).
Heterozygous for KRAS p.Gly13Asp (c.38G>A) (ClinVar=VCV000012580) (from parent cell line).
TERT c.228C>T (-124C>T); in promoter (from parent cell line).
Homozygous for TP53 p.Arg280Lys (c.839G>A) (ClinVar=VCV000376657) (from parent cell line).
Disease Breast adenocarcinoma (NCIt: C5214)
Derived from metastatic site: Pleural effusion.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0062 (MDA-MB-231)
Sex of cell Female
Age at sampling 51Y
Category Cancer cell line
Publications

CLPUB00286
Sprouse A.A.
Resveratrol augments paclitaxel treatment in MDA-MB-231 and paclitaxel-resistant MDA-MB-231 breast cancer cells.
Thesis PhD (2014), University of Indiana, United States

PubMed=25275030
Sprouse A.A., Herbert B.-S.
Resveratrol augments paclitaxel treatment in MDA-MB-231 and paclitaxel-resistant MDA-MB-231 breast cancer cells.
Anticancer Res. 34:5363-5374(2014)

Cross-references
Other Wikidata; Q54904617
Entry history
Entry creation14-Dec-2015
Last entry update02-Jul-2020
Version number10